ABUS · Insider Trading
Arbutus Biopharma Corporation Common Stock
Every open-market purchase and sale reported by ABUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | Roger Sawhney | Director | D | −17,142 | −$85.71K |
| 2026-10-07 | Tuan Nguyen | Chief Financial Officer | D | −48,081 | −$240.41K |
| 2026-10-07 | Lindsay Androski | President and CEO | D | −24,655 | −$123.28K |
| 2026-10-07 | Robert A Beardsley | Director | D | −17,948 | −$89.74K |
| 2026-10-05 | Roivant Sciences Ltd. | Director | D | −8,967,383 | −$44.84M |
| 2026-09-23 | Tuan Nguyen | Chief Financial Officer | MIXED | +86,463 | −$3 |
| 2026-09-23 | Lindsay Androski | President and CEO | MIXED | +44,337 | −$4 |
| 2026-09-23 | Robert A Beardsley | Director | MIXED | +32,276 | −$1 |
| 2026-09-23 | Roger Sawhney | Director | MIXED | +30,825 | −$3 |
| 2026-06-10 | Robert A Beardsley | Director | A | +78,800 deriv. | — |
| 2026-06-10 | Roger Sawhney | Director | A | +78,800 deriv. | — |
| 2026-02-02 | Lindsay Androski | President and CEO | A | +28,000 | — |
| 2026-02-02 | Tuan Nguyen | Chief Financial Officer | A | +73,500 | — |
| 2025-08-06 | Roger Sawhney | Director | A | +157,600 deriv. | — |
| 2025-04-01 | Tuan Nguyen | Chief Financial Officer | A | +750,000 deriv. | — |
| 2025-03-31 | Tuan Nguyen | Chief Financial Officer | A | +750,000 deriv. | — |
| 2025-03-20 | Anuj Hasija | Director | A | +157,600 deriv. | — |
| 2025-03-20 | Robert A Beardsley | Director | A | +157,600 deriv. | — |
| 2025-03-20 | Lindsay Androski | President and CEO | A | +310,422 deriv. | — |
| 2025-02-19 | Karen Sims | Chief Medical Officer | A | +49,300 | — |
| 2025-02-19 | Michael J. McElhaugh | Interim President & CEO | A | +177,000 | — |
| 2025-02-19 | David C Hastings | Chief Financial Officer | A | +90,100 | — |
| 2025-02-19 | J. Christopher Naftzger | General Counsel and CCO | A | +54,300 | — |
| 2025-02-05 | J. Christopher Naftzger | General Counsel and CCO | Sell | −11,333 | −$37.21K |
| 2025-02-05 | David C Hastings | Chief Financial Officer | Sell | −22,183 | −$72.83K |
| 2025-02-05 | Michael J. McElhaugh | Interim President & CEO | Sell | −23,790 | −$78.10K |
| 2025-02-05 | Karen Sims | Chief Medical Officer | Sell | −19,348 | −$63.52K |
| 2024-08-16 | Keith S Manchester | Director | MIXED | +46,069 | −$1.88K |
| 2024-05-24 | Keith S Manchester | Director | A | +67,000 deriv. | — |
| 2024-05-24 | Frank Torti | Director | A | +67,000 deriv. | — |
| 2024-05-24 | Melissa Rewolinski | Director | A | +67,000 deriv. | — |
| 2024-05-24 | James R Meyers | Director | A | +67,000 deriv. | — |
| 2024-05-24 | Daniel D Burgess | Director | A | +67,000 deriv. | — |
| 2024-05-24 | Richard C Henriques Jr | Director | A | +67,000 deriv. | — |
| 2024-02-05 | David C Hastings | Chief Financial Officer | MIXED | +102,907 | −$22.18K |
| 2024-02-05 | Michael J. McElhaugh | Interim President & CEO | MIXED | +113,636 | −$23.50K |
| 2024-02-05 | Michael J. Sofia | Chief Scientific Officer | MIXED | +99,518 | −$23.08K |
| 2024-02-05 | Karen Sims | Chief Medical Officer | MIXED | +96,642 | −$10.08K |
| 2024-02-05 | J. Christopher Naftzger | General Counsel and CCO | A | +95,100 | — |
| 2023-07-13 | Melissa Rewolinski | Director | A | +110,000 deriv. | — |
| 2023-07-12 | J. Christopher Naftzger | General Counsel and CCO | A | +500,000 deriv. | — |
| 2023-07-12 | Karen Sims | Chief Medical Officer | A | +153,640 deriv. | — |
| 2023-05-26 | James R Meyers | Director | A | +55,000 deriv. | — |
| 2023-05-26 | Daniel D Burgess | Director | A | +55,000 deriv. | — |
| 2023-05-26 | Richard C Henriques Jr | Director | A | +55,000 deriv. | — |
| 2023-05-26 | Keith S Manchester | Director | A | +55,000 deriv. | — |
| 2023-05-26 | Frank Torti | Director | A | +55,000 deriv. | — |
| 2023-02-03 | William H. Collier | President and CEO | A | +216,500 | — |
| 2023-02-03 | David C Hastings | Chief Financial Officer | A | +79,000 | — |
| 2023-02-03 | Michael J. Sofia | Chief Scientific Officer | A | +82,200 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Roivant Sciences Ltd. | Director | 29,880,079 | $126.09M |
| Michael J. McElhaugh | Interim President & CEO | 1,658,003 | $7.00M |
| David C Hastings | Chief Financial Officer | 249,824 | $1.05M |
| Karen Sims | Chief Medical Officer | 155,494 | $656.18K |
| J. Christopher Naftzger | General Counsel and CCO | 140,544 | $593.10K |
| Tuan Nguyen | Chief Financial Officer | 111,882 | $472.14K |
| Lindsay Androski | President and CEO | 47,682 | $201.22K |
| Robert A Beardsley | Director | 14,328 | $60.46K |
| Roger Sawhney | Director | 13,683 | $57.74K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ABUS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.